Direct MSC to Cardiomyocyte Conversion via Nucleotide Transcription Factors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The mass production of autologous cardiomyocytes for regenerative applications in cardiac failure remains a significant obstacle due to the inefficiency and time-consuming nature of existing cellular transdifferentiation methods, particularly relying on induced pluripotent stem cells.
Innovation Solution
A composition comprising ribonucleotides or deoxyribonucleotides encoding specific cell fate determinants such as PBX2, ACTN2, POU2F1, HAND1, GATA4, and others is used to reprogram mesenchymal stem cells into autologous induced cardiomyocytes, leveraging deep learning algorithms like NETZEN to identify optimal combinations for efficient transdifferentiation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If induced pluripotent stem cell intermediary method is used for cellular transdifferentiation, then cardiomyocytes can be generated, but the process is highly inefficient and time consuming
Solution Approach 1:
The invention extracts and eliminates the intermediate pluripotent stem cell stage from the transdifferentiation process. By directly converting mesenchymal stem cells to cardiomyocytes through specific transcription factor delivery (GATA4, HAND2, TBX5), the method removes the inefficient intermediary step while maintaining reliable cardiomyocyte generation
Solution Approach 2:
The invention introduces small molecule compounds as intermediaries to directly mediate the conversion from mesenchymal stem cells to cardiomyocytes. These small molecules act as mediators that reprogram cell fate without requiring passage through pluripotent states, thereby improving efficiency
2Reliability
If induced pluripotent stem cell intermediary method is used for cellular transdifferentiation, then cardiomyocytes can be generated, but the process is time consuming
Solution Approach 1:
By removing the intermediate pluripotent stem cell stage from the differentiation pathway, the invention dramatically shortens the time required for cardiomyocyte generation. The direct conversion approach eliminates multiple culture and differentiation steps, reducing overall process duration while maintaining reliability
Solution Approach 2:
The invention performs preliminary reprogramming actions by delivering specific transcription factors and small molecules that directly induce cardiomyocyte fate. This preliminary action bypasses lengthy intermediate stages and accelerates the overall process
3Productivity
If direct CM conversion is used, then mass production of autologous CMs can be achieved, but it remains the main obstacle to clinical reality
Solution Approach 1:
The invention uses the patient's own mesenchymal stem cells (autologous) as the starting material, which self-renew and can be expanded in culture. This self-service approach eliminates the need for donor cells and reduces immun rejection risks, improving clinical applicability while maintaining high productivity
Solution Approach 2:
The invention changes key parameters of the transdifferentiation process by using specific transcription factor combinations (GATA4, HAND2, TBX5) and small molecule compounds. These parameter changes optimize both the efficiency of conversion and the quality of resulting cardiomyocytes, making the process suitable for clinical application
Data Source
AI summary
The invention provides compositions comprising a ribonucleotide or ribonucleotides or a deoxyribonucleotide or deoxyribonucleotides encoding at least two cell fate determinants (CFD) selected from the group consisting of PBX2, ACTN2, POU2F1, HAND1, TRIM24, GATA4, PBX1, ZBTB39, HAND2, IKZF4, NROB2, NACA2, SMYD1, JUP, NEUROD1, CKMT2, TSHZ2, MITF, MYOCD, and PPARGC1B. The compositions are useful in the treatment of cardiac disorders and in reprogramming a mesenchymal stem cell (MSC) to an autologous induced cardiomyocyte (iCM).